Literature DB >> 33191286

Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease.

Vanessa L Kronzer1, Weixing Huang2, Paul F Dellaripa2, Sicong Huang2, Vivi Feathers2, Bing Lu2, Christine K Iannaccone3, Ritu R Gill4, Hiroto Hatabu5, Mizuki Nishino6, Cynthia S Crowson7, John M Davis1, Michael E Weinblatt2, Nancy A Shadick2, Tracy J Doyle8, Jeffrey A Sparks9.   

Abstract

OBJECTIVE: To determine the association between novel lifestyle factors on risk of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), define the threshold at which smoking increases RA-ILD risk, and calculate the degree to which known lifestyle and clinical factors predict RA-ILD.
METHODS: This nested case-control study matched incident RA-ILD cases to RA non-ILD controls on age, sex, RA duration, rheumatoid factor, and time from exposure assessment to RA-ILD. Exposures included education, BMI, smoking, anticyclic citrullinated peptide antibodies, race, joint erosions, rheumatoid nodules, C-reactive protein (CRP), disease activity score, functional status, disease-modifying antirheumatic drug use, and glucocorticoid use. OR for each exposure on risk of RA-ILD were obtained from logistic regression models. Area under the curve (AUC) was calculated based on all lifestyle and clinical exposures.
RESULTS: We identified 84 incident RA-ILD cases and 233 matched controls. After adjustment, obesity, high-positive CRP (≥ 10 mg/L), and poor functional status (multidimensional Health Assessment Questionnaire [MDHAQ] ≥ 1) were associated with increased risk of RA-ILD (OR 2.42, 95% CI 1.11-5.24 vs normal BMI; OR 2.61, 95% CI 1.21-5.64 vs CRP < 3 mg/L; OR 3.10, 95% CI 1.32-7.26 vs MDHAQ < 0.2). Smoking 30 pack-years or more was strongly associated with risk of RA-ILD compared to never smokers (OR 6.06, 95% CI 2.72-13.5). Together, lifestyle and clinical risk factors for RA-ILD had an AUC of 0.79 (95% CI 0.73-0.85).
CONCLUSION: Obesity, CRP, functional status, and extensive smoking may be novel risk factors for RA-ILD that may be useful for RA-ILD risk assessment and prevention. The overall ability to predict RA-ILD remains modest.
Copyright © 2021 by the Journal of Rheumatology.

Entities:  

Keywords:  interstitial lung disease; obesity; respiratory diseases; rheumatoid arthritis

Mesh:

Year:  2020        PMID: 33191286      PMCID: PMC8096643          DOI: 10.3899/jrheum.200863

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  47 in total

1.  Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.

Authors:  Tim Bongartz; Carlotta Nannini; Yimy F Medina-Velasquez; Sara J Achenbach; Cynthia S Crowson; Jay H Ryu; Robert Vassallo; Sherine E Gabriel; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2010-06

2.  Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.

Authors:  Clive A Kelly; Vadivelu Saravanan; Mohamed Nisar; Subha Arthanari; Felix A Woodhead; Alec N Price-Forbes; Julie Dawson; Navtej Sathi; Yasmeen Ahmad; Gouri Koduri; Adam Young
Journal:  Rheumatology (Oxford)       Date:  2014-04-23       Impact factor: 7.580

3.  Socioeconomic status and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study.

Authors:  C Bengtsson; B Nordmark; L Klareskog; I Lundberg; L Alfredsson
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

4.  Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis.

Authors:  Dam Kim; Soo-Kyung Cho; Chan-Bum Choi; Jung-Yoon Choe; Won Tae Chung; Seung-Jae Hong; Jae-Bum Jun; Young Ok Jung; Tae-Hwan Kim; Tae-Jong Kim; Hye-Soon Lee; Joo-Hyun Lee; Jisoo Lee; Shin-Seok Lee; Dae-Hyun Yoo; Bo Young Yoon; Jin Woo Song; Sang-Cheol Bae; Yoon-Kyoung Sung
Journal:  Rheumatol Int       Date:  2017-07-26       Impact factor: 2.631

5.  The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus.

Authors:  E W Karlson; L H Daltroy; R A Lew; E A Wright; A J Partridge; A H Fossel; W N Roberts; S H Stern; K V Straaton; M C Wacholtz; A F Kavanaugh; J M Grosflam; M H Liang
Journal:  Arthritis Rheum       Date:  1997-01

6.  Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study.

Authors:  Jeffrey A Sparks; Xintong He; Jie Huang; Elaine A Fletcher; Alessandra Zaccardelli; H Maura Friedlander; Ritu R Gill; Hiroto Hatabu; Mizuki Nishino; David J Murphy; Christine K Iannaccone; Taysir G Mahmoud; Michelle L Frits; Bing Lu; Ivan O Rosas; Paul F Dellaripa; Michael E Weinblatt; Elizabeth W Karlson; Nancy A Shadick; Tracy J Doyle
Journal:  Arthritis Rheumatol       Date:  2019-08-04       Impact factor: 10.995

7.  Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias.

Authors:  Eric S White; Meng Xia; Susan Murray; Rachel Dyal; Candace M Flaherty; Kevin R Flaherty; Bethany B Moore; Ling Cheng; Tracy J Doyle; Julian Villalba; Paul F Dellaripa; Ivan O Rosas; Jonathan D Kurtis; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2016-11-15       Impact factor: 21.405

Review 8.  Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature.

Authors:  George E Fragoulis; Richard Conway; Elena Nikiphorou
Journal:  Rheumatology (Oxford)       Date:  2019-11-01       Impact factor: 7.580

9.  High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalities.

Authors:  Fausto Salaffi; Marina Carotti; Marco Di Carlo; Marika Tardella; Andrea Giovagnoni
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.889

10.  Anti-cyclic citrullinated Peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis.

Authors:  Yufeng Yin; Di Liang; Lidan Zhao; Yang Li; Wei Liu; Yan Ren; Yongzhe Li; Xiaofeng Zeng; Fengchun Zhang; Fulin Tang; Guangliang Shan; Xuan Zhang
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

View more
  6 in total

1.  Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)-associated Bronchiectasis: Role of RA-related Autoantibodies.

Authors:  Gregory McDermott; Ritu Gill; Staci Gagne; Suzanne Byrne; Weixing Huang; Xiaosong Wang; Lauren C Prisco; Alessandra Zaccardelli; Lily W Martin; Lucy Masto; Vanessa L Kronzer; Nancy Shadick; Paul F Dellaripa; Tracy J Doyle; Jeffrey A Sparks
Journal:  J Rheumatol       Date:  2022-03-15       Impact factor: 5.346

2.  Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort.

Authors:  Bilal F Samhouri; Robert Vassallo; Sara J Achenbach; Vanessa L Kronzer; John M Davis; Elena Myasoedova; Cynthia S Crowson
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-01-07       Impact factor: 5.178

3.  Development of a Risk Nomogram Model for Identifying Interstitial Lung Disease in Patients With Rheumatoid Arthritis.

Authors:  Jing Xue; Wenfeng Hu; Shuang Wu; Jing Wang; Shuhong Chi; Xiaoming Liu
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

Review 4.  Interstitial lung disease throughout the rheumatoid arthritis disease course.

Authors:  Gregory C McDermott; Tracy J Doyle; Jeffrey A Sparks
Journal:  Curr Opin Rheumatol       Date:  2021-05-01       Impact factor: 5.006

5.  Genetically Determined Chronic Low-Grade Inflammation and Hundreds of Health Outcomes in the UK Biobank and the FinnGen Population: A Phenome-Wide Mendelian Randomization Study.

Authors:  Shucheng Si; Jiqing Li; Marlvin Anemey Tewara; Fuzhong Xue
Journal:  Front Immunol       Date:  2021-07-27       Impact factor: 7.561

6.  Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers.

Authors:  Antti Palomäki; Aarno Palotie; Jukka Koskela; Kari K Eklund; Matti Pirinen; Samuli Ripatti; Tarja Laitinen; Nina Mars
Journal:  Ann Rheum Dis       Date:  2021-08-03       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.